News & Events

Read about the latest company news, thought leadership, publications and events

Recent News

October 16, 2018 Cerecin appoints two new members to its Scientific Advisory Board following announcement of new Singapore headquarters

October 4, 2018 Accera closes new investment led by Asia's leading agribusiness group, Wilmar, and rebrands as Cerecin

September 12, 2018 Dr. Charles Stacey, Cerecin's President and CEO is appointed to the Board of Governors of the Accreditation Council for Medical Affairs (ACMA)

July 12, 2017 Cerecin Enters into a Strategic Partnership and Exclusive Licensing Agreement with DuChemBio for Cerecin's Technology in Korea

May 4, 2017 Cerecin appoints Dr. Judy Walker as Chief Medical Officer

February 28, 2017 Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's Disease

November 30, 2016 Beyond the Failed Beta Amyloid Hypothesis

November 28, 2016 Interview – Accera next up in Alzheimer's disease

November 28, 2016 So long to Sola; Lilly bloom's hope withers big pharma continues to ‘Chase' AD dream

September 26, 2016 Accera to Present at Upcoming Healthcare and Investor Conferences

September 8, 2016 Accera Appoints Jeffrey Cummings and Bruno Vellas to Scientific Advisory Board

August 2, 2016 Accera Appoints C. Evan Ballantyne as Chief Financial Officer

May 12, 2016 Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for Alzheimer's Disease Treatment

May 5, 2016 Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

April 27, 2016 Broomfield Biotech Firm Accera Moves to Boulder

April 20, 2016 Bioscience roundtable: Attracting development capital, talent top of mind in Colorado

March 10, 2016 Accera to Present at BIO Asia International Conference

March 8, 2016 Accera Appoints Ernest Wong, Ph.D., as Head of Corporate Development

September 17, 2015 Accera Supports World Alzheimer's Day

July 14, 2015 Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease

July 2, 2015 Accera Hoping for an Alzheimer's Breakthrough

June 24, 2015 Accera Pivots From Medical Foods to Potential Drug for Alzheimer's

June 10, 2015 Accera Appoints Dr. Charles Stacey, M.D., as President and CEO

February 20, 2015 Dr. Samuel Henderson, Accera's V.P. of Research and Development, to Present at the 249th American Chemical Society National Meeting

January 14, 2014 Accera statement on FDA warning letter

November 12, 2013 Accera, Inc. to Moderate Symposium on Metabolic Dysregulation in Alzheimer's Disease During the 6th Annual Clinical Trials Conference on Alzheimer's Disease (CTAD)

October 28, 2013 Accera, Inc. Announces Publication of Results in the Journal Neuropsychiatric Disease and Treatment of a Retrospective Cohort Study Examining the Effects of Axona® in Patients With Mild-to-Moderate Alzheimer's Disease

April 9, 2013 Accera and the University of Miami Miller School of Medicine Announce Collaboration to Study Axona® for Cognitive Impairment in Patients with Multiple Sclerosis

March 1, 2013 Accera, Inc. Introduces Axona® Patient Starter Kits for Alzheimer's Disease Patients Beginning Therapy

October 5, 2010 Accera, Inc. Appoints Dr. Thomas Werner President & CEO and Announces FDA Acceptance of IND Application for AC-1204 for Mild-to-Moderate Alzheimer's Disease

March 9, 2010 New Evidence Further Validates Ketone Body Therapy as an Effective Approach in Managing Alzheimer's Disease

February 1, 2010 Accera, Inc. to Present at the 3rd Annual European Life Science CEO Forum for Partnering & Investing

November 23, 2009 Tips for Caregivers and a New Therapy Offers Hope in the Fight Against Alzheimer's

November 17, 2009 Accera, Inc. Announces Culmination of Lost & Found Campaign: Company Donates $25,000 to the Alzheimer's Foundation of America for National Memory Screening Day

November 11, 2009 Accera, Inc. Awarded "Company of the Year" by the Colorado BioScience Association

November 11, 2009 Accera, Inc. to Present at Lazard Capital Markets 6th Annual Healthcare Conference

September 18, 2009 Accera Inc. to Present at UBS Global Life Sciences Conference

August 12, 2009 Accera Announces Peer-Reviewed Publication of the Results of its 90-day Clinical Study of AC-1202 (Axona™) in Mild to Moderate Alzheimer's Disease

August 11, 2009 Accera, Inc. to Support the Alzheimer's Foundation of America's National Memory Screening Day through On-line Awareness Effort

July 27, 2009 Accera, Inc. Announces Dr. Gunnar Weikert Elected to Board of Directors

July 14, 2009 Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease

April 15, 2009 Accera, Inc. Launches Neuera Pharmaceuticals, Inc.

March 25, 2009 Accera, Inc. to Present at Upcoming Investor Conferences

March 24, 2009 Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors

March 2, 2009 Accera Launches Axona™, First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease

February 19, 2009 Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference


October 5-9, 2018 KETO 2018, 8th Global Symposium on Ketogenic Therapies for Neurological Disorders- Presentation by Sam Henderson, Cerecin's Chief Scientific Officer
Jeju, Korea

October 11, 2018 IQVIA 2018 APAC Healthcare Summit- Human Science Meet Data Science

October 24-27, 2018 CTAD-Alzheimer | 11th Clinical Trials on Alzheimer's disease
Barcelona, Spain

October 31- November 2, 2018 Biotech Investment Summit- Panel discussion with Cerecin's President and CEO, Charles Stacey

January 7-9, 2019 JP Morgan Healthcare Conference
San Francisco, USA